HK1259433A1 - 包含btk抑制劑的配製品/組合物 - Google Patents

包含btk抑制劑的配製品/組合物

Info

Publication number: HK1259433A1
Authority: HK; Hong Kong
Prior art keywords: formulations; compositions; btk inhibitor; btk; inhibitor
Prior art date: 2016-01-19

Application number

HK19101837.4A

Other languages

English (en)

Inventor

Manish Kumar Gupta

Parikshit Rameshrao Kulkarni

Nair Binuraj Krishnan

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-01-19

Filing date

2019-02-01

Publication date

2019-11-29

2019-02-01 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2019-11-29 Publication of HK1259433A1 publication Critical patent/HK1259433A1/zh

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

HK19101837.4A 2016-01-19 2019-02-01 包含btk抑制劑的配製品/組合物 HK1259433A1 (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IN201621001987		2016-01-19
PCT/EP2017/050964 WO2017125424A1 (en)	2016-01-19	2017-01-18	Formulations/compositions comprising a btk inhibitor

Publications (1)

Publication Number	Publication Date
HK1259433A1 true HK1259433A1 (zh)	2019-11-29

Family

ID=57851068

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HK19101845.4A HK1259441A1 (zh)	2016-01-19	2019-02-01	包含btk抑制劑的製劑/組合物
HK19101837.4A HK1259433A1 (zh)	2016-01-19	2019-02-01	包含btk抑制劑的配製品/組合物

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
HK19101845.4A HK1259441A1 (zh)	2016-01-19	2019-02-01	包含btk抑制劑的製劑/組合物

Country Status (15)

Country	Link
US (3)	US20190290650A1 (zh)
EP (1)	EP3405178A1 (zh)
JP (2)	JP7336195B2 (zh)
KR (1)	KR20180102150A (zh)
CN (2)	CN114681462A (zh)
AR (1)	AR107392A1 (zh)
AU (1)	AU2017208473B2 (zh)
BR (1)	BR112018014540B1 (zh)
CA (1)	CA3008576A1 (zh)
EA (1)	EA201891664A1 (zh)
HK (2)	HK1259441A1 (zh)
MA (1)	MA43650A (zh)
MX (2)	MX2018008772A (zh)
TW (1)	TWI794153B (zh)
WO (1)	WO2017125424A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN110354132A (zh)	2012-06-04	2019-10-22	药品循环有限责任公司	布鲁顿酪氨酸激酶抑制剂的晶形
TW202315634A (zh) *	2015-03-03	2023-04-16	美商製藥公司	布魯東氏（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶抑制劑之醫藥調配物
CA3089537A1 (en)	2018-01-20	2019-07-25	Natco Pharma Limited	Pharmaceutical compositions comprising ibrutinib
EP3575300A1 (en)	2018-05-31	2019-12-04	Apotex Inc.	Novel crystalline forms of ibrutinib
CN112292117A (zh)	2018-06-15	2021-01-29	詹森药业有限公司	包含依鲁替尼的配制品/组合物
US10688050B1 (en) *	2018-12-21	2020-06-23	Synthon B.V.	Pharmaceutical composition comprising ibrutinib

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4327725A (en)	1980-11-25	1982-05-04	Alza Corporation	Osmotic device with hydrogel driving member
US4624848A (en)	1984-05-10	1986-11-25	Ciba-Geigy Corporation	Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en)	1987-07-27	1990-11-06	Mcneilab, Inc.	Oral sustained release acetaminophen formulation and process
IL92966A (en)	1989-01-12	1995-07-31	Pfizer	Hydrogel-operated release devices
KR0182801B1 (ko)	1991-04-16	1999-05-01	아만 히데아키	고체 분산체의 제조방법
WO1993009785A1 (en)	1991-11-22	1993-05-27	Procter & Gamble Pharmaceuticals, Inc.	Risedronate delayed-release compositions
US5461140A (en)	1992-04-30	1995-10-24	Pharmaceutical Delivery Systems	Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en)	1992-06-23	1994-06-28	Multi-Comp, Inc.	Child resistant package assembly for dispensing pharmaceutical medications
CA2147283C (en)	1992-10-16	2007-01-16	Kouichi Nakamichi	Method of manufacturing wax matrices
US5686105A (en)	1993-10-19	1997-11-11	The Procter & Gamble Company	Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US6326469B1 (en)	1994-04-22	2001-12-04	Sugen, Inc.	Megakaryocytic protein tyrosine kinases
CA2220451A1 (en)	1995-05-17	1996-11-21	Cedars-Sinai Medical Center	Methods and compositions for improving digestion and absorption in the small intestine
US6395300B1 (en)	1999-05-27	2002-05-28	Acusphere, Inc.	Porous drug matrices and methods of manufacture thereof
US6465014B1 (en)	2001-03-21	2002-10-15	Isp Investments Inc.	pH-dependent sustained release, drug-delivery composition
EP2157524A3 (en)	2003-09-03	2010-12-08	GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Methods for identifying, diagnosing, and predicting survival of lymphomas
KR101315610B1 (ko)	2006-09-22	2013-10-10	파마시클릭스, 인코포레이티드	브루톤 티로신 키나제 억제제
CN110801454A (zh) *	2011-10-19	2020-02-18	药品循环有限责任公司	布鲁顿酪氨酸激酶(btk)抑制剂的用途
CN110354132A (zh) *	2012-06-04	2019-10-22	药品循环有限责任公司	布鲁顿酪氨酸激酶抑制剂的晶形
WO2014004707A1 (en) *	2012-06-29	2014-01-03	Principia Biopharma Inc.	Formulations comprising ibrutinib
US20160022683A1 (en) *	2013-03-14	2016-01-28	Pharmacyclics Llc	Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors
WO2015071432A1 (en) *	2013-11-14	2015-05-21	Sandoz Ag	Pharmaceutical compositions of ibrutinib
CN104523695A (zh) *	2014-11-12	2015-04-22	广东东阳光药业有限公司	一种治疗过度增生性疾病的药物组合物

2017
- 2017-01-18 AU AU2017208473A patent/AU2017208473B2/en active Active
- 2017-01-18 BR BR112018014540-8A patent/BR112018014540B1/pt active IP Right Grant
- 2017-01-18 CN CN202210154359.9A patent/CN114681462A/zh active Pending
- 2017-01-18 CA CA3008576A patent/CA3008576A1/en active Pending
- 2017-01-18 EA EA201891664A patent/EA201891664A1/ru unknown
- 2017-01-18 MX MX2018008772A patent/MX2018008772A/es unknown
- 2017-01-18 KR KR1020187023229A patent/KR20180102150A/ko unknown
- 2017-01-18 MA MA043650A patent/MA43650A/fr unknown
- 2017-01-18 CN CN201780006739.5A patent/CN108472258A/zh active Pending
- 2017-01-18 EP EP17700821.6A patent/EP3405178A1/en active Pending
- 2017-01-18 WO PCT/EP2017/050964 patent/WO2017125424A1/en active Application Filing
- 2017-01-18 JP JP2018556012A patent/JP7336195B2/ja active Active
- 2017-01-18 US US16/071,453 patent/US20190290650A1/en not_active Abandoned
- 2017-01-19 TW TW106101787A patent/TWI794153B/zh active
- 2017-01-19 AR ARP170100142A patent/AR107392A1/es unknown
2018
- 2018-07-17 MX MX2022006817A patent/MX2022006817A/es unknown
2019
- 2019-02-01 HK HK19101845.4A patent/HK1259441A1/zh unknown
- 2019-02-01 HK HK19101837.4A patent/HK1259433A1/zh unknown
2021
- 2021-02-11 US US17/174,305 patent/US20210169888A1/en not_active Abandoned
2022
- 2022-04-07 JP JP2022063752A patent/JP2022105006A/ja active Pending
- 2022-11-22 US US17/992,348 patent/US20230364090A1/en active Pending

Also Published As

Publication number	Publication date
CA3008576A1 (en)	2017-07-27
TW201737918A (zh)	2017-11-01
AU2017208473B2 (en)	2022-04-21
EP3405178A1 (en)	2018-11-28
AR107392A1 (es)	2018-04-25
JP2019506450A (ja)	2019-03-07
AU2017208473A1 (en)	2018-07-12
MX2018008772A (es)	2018-11-09
HK1259441A1 (zh)	2019-11-29
CN108472258A (zh)	2018-08-31
CN114681462A (zh)	2022-07-01
US20210169888A1 (en)	2021-06-10
MX2022006817A (es)	2022-07-11
MA43650A (fr)	2018-11-28
KR20180102150A (ko)	2018-09-14
WO2017125424A1 (en)	2017-07-27
TWI794153B (zh)	2023-03-01
US20190290650A1 (en)	2019-09-26
JP2022105006A (ja)	2022-07-12
US20230364090A1 (en)	2023-11-16
BR112018014540B1 (pt)	2024-02-27
BR112018014540A2 (pt)	2018-12-11
JP7336195B2 (ja)	2023-08-31
EA201891664A1 (ru)	2019-02-28

Publication	Publication Date	Title
HK1259434A1 (zh)	2019-11-29	包含btk抑制劑的配製品/組合物
ZA201606074B (en)	2018-04-25	Compositions comprising a bittering agent
IL260933A (en)	2018-10-31	Preparations containing tocorsol or its analogues
IL261792B (en)	2022-06-01	Preparations
HK1259441A1 (zh)	2019-11-29	包含btk抑制劑的製劑/組合物
GB201610156D0 (en)	2016-07-27	Cliptac compositions
GB2543681B (en)	2017-07-26	Negative-tone resist compositions
PT3523389T (pt)	2022-04-13	Composições azeotrópicas com base em tetrafluoropropeno
IL287830A (en)	2022-01-01	Prodrug compounds of monomethyl fumarate
FI3595667T3 (fi)	2024-01-12	Farmaseuttiset koostumukset, joihin sisältyy jak-estäjän tausta
GB201614799D0 (en)	2016-10-19	Compositions
GB201622161D0 (en)	2017-02-08	Compositions
SG11201803734XA (en)	2018-06-28	Cleanser composition for a pump-foamer
CL2016003154A1 (es)	2017-08-18	Composiciones herbicidas sólidas que contienen un fitoprotector
CL2016003128A1 (es)	2017-08-18	Composiciones herbicidas sólidas que contienen un protector
GB201601838D0 (en)	2016-03-16	A composition
IL273778B (en)	2022-06-01	Compounds of btk inhibitors
GB201518909D0 (en)	2015-12-09	A formulation
GB201602658D0 (en)	2016-03-30	Compositions
IL259215A (en)	2018-07-31	Hiv maturation inhibitor formulations
ZA201703367B (en)	2019-04-24	A composition
GB201614230D0 (en)	2016-10-05	Compositions
GB201611084D0 (en)	2016-08-10	Vaccine compositions
GB201611960D0 (en)	2016-08-24	Compositions
GB201611851D0 (en)	2016-08-24	Compositions